Literature DB >> 11770985

The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens.

C C Breathnach1, M R Yeargan, A S Sheoran, G P Allen.   

Abstract

Equine herpesvirus-1 (EHV-1) remains a frequent cause of upper respiratory tract infection and abortion in horses worldwide. However, little is known about the local antibody response elicited in the upper airways of horses following exposure to EHV-1. This study analysed the mucosal humoral immune response of weanling foals following experimental infection with virulent EHV-1, or vaccination with either of 2 commercial vaccines. Twenty weanlings were assigned to 5 groups and were inoculated with, or vaccinated against, EHV-1 following different regimens. Finally, all weanlings were simultaneously challenged intranasally with virulent EHV-1 Army 183 (A183). Nasal wash and serum samples were collected at regular intervals until 13 weeks after final challenge. Nasal washes were assayed for EHV-1-specific equine IgGa, IgGb, IgG(T), IgA, IgM and total virus-specific antibody using an indirect, quantitative ELISA. Total serum antibody responses were also monitored, and clinical signs of EHV-disease were recorded for each individual. Virus-specific IgA dominated the mucosal antibody response elicited in weanlings inoculated with A183, being detectable at up to 3.1 microg/mg total IgA 13 weeks after challenge. Neither inactivated EHV-1 administered i.m., nor attenuated EHV-1 administered intranasally induced detectable mucosal antibodies. EHV-1-specific mucosal antibodies impeded EHV-1 plaque formation in vitro. Such virus-neutralising antibody probably contributes to a reduction of shedding of EHV-1 from the respiratory tract of virus-infected horses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11770985     DOI: 10.2746/042516401776249318

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  6 in total

1.  An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.

Authors:  Christiane L Schnabel; Susanna Babasyan; Alicia Rollins; Heather Freer; Christine L Wimer; Gillian A Perkins; Fahad Raza; Nikolaus Osterrieder; Bettina Wagner
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Equine herpesvirus type 4 UL56 and UL49.5 proteins downregulate cell surface major histocompatibility complex class I expression independently of each other.

Authors:  Abdelrahman Said; Walid Azab; Armando Damiani; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  Immunological correlates of vaccination and infection for equine herpesvirus 1.

Authors:  Laura B Goodman; Christine Wimer; Edward J Dubovi; Carvel Gold; Bettina Wagner
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

4.  Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.

Authors:  Helga Hofmann-Sieber; Jens Wild; Nicole Fiedler; Karsten Tischer; Jens von Einem; Nikolaus Osterrieder; Heike Hofmann; Josef Köstler; Ralf Wagner
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

5.  IgA in the horse: cloning of equine polymeric Ig receptor and J chain and characterization of recombinant forms of equine IgA.

Authors:  M J Lewis; B Wagner; R M Irvine; J M Woof
Journal:  Mucosal Immunol       Date:  2010-07-14       Impact factor: 7.313

6.  Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity.

Authors:  Christiane L Schnabel; Christine L Wimer; Gillian Perkins; Susanna Babasyan; Heather Freer; Christina Watts; Alicia Rollins; Nikolaus Osterrieder; Bettina Wagner
Journal:  BMC Vet Res       Date:  2018-08-22       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.